Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Clearmind Medicine Inc. (Nasdaq: CMND) has received a new patent approval from the United States Patent and Trademark Office for its MEAI-based binge behavior regulator program. The patent covers methods of regulating alcoholic beverage consumption and controlling binge behavior through the administration of amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule.
This approval strengthens Clearmind's intellectual property portfolio, which now includes 29 granted patents across 19 patent families in key jurisdictions such as the U.S., Europe, China, and India. MEAI is a novel psychoactive molecule that reduces the desire to consume alcohol while providing a mild euphoric, alcohol-like experience. Clearmind's MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss, with potential applications in treating binge drinking.
Clearmind Medicine Inc. (Nasdaq: CMND) ha ricevuto una nuova approvazione di brevetto dall'Ufficio Brevetti e Marchi degli Stati Uniti per il suo programma di regolazione del comportamento da binge basato su MEAI. Il brevetto riguarda metodi per regolare il consumo di bevande alcoliche e controllare il comportamento da binge attraverso l'amministrazione di amina aminoindano, inclusa la 5-metossiaminoindan (MEAI), la molecola psichedelica innovativa della società.
Questa approvazione rafforza il portafoglio di proprietà intellettuale di Clearmind, che ora include 29 brevetti concessi distribuiti su 19 famiglie di brevetti in giurisdizioni chiave come gli Stati Uniti, l'Europa, la Cina e l'India. MEAI è una molecola psicoattiva innovativa che riduce il desiderio di consumare alcol, offrendo al contempo un'esperienza euforica leggera simile a quella dell'alcol. Il trattamento di punta di Clearmind basato su MEAI mira a disturbo da uso di alcol (AUD) e perdita di peso, con potenziali applicazioni nel trattamento del binge drinking.
Clearmind Medicine Inc. (Nasdaq: CMND) ha recibido una nueva aprobación de patente de la Oficina de Patentes y Marcas de EE. UU. para su programa regulador de comportamiento binge basado en MEAI. La patente cubre métodos para regular el consumo de bebidas alcohólicas y controlar el comportamiento binge a través de la administración de amina aminoindano, incluyendo 5-metoxiaminoindan (MEAI), la innovadora molécula psicodélica de la compañía.
Esta aprobación refuerza el portafolio de propiedad intelectual de Clearmind, que ahora incluye 29 patentes otorgadas en 19 familias de patentes en jurisdicciones clave como EE. UU., Europa, China e India. MEAI es una molécula psicoactiva novedosa que reduce el deseo de consumir alcohol mientras proporciona una ligera experiencia eufórica similar al alcohol. El tratamiento insignia de Clearmind basado en MEAI se dirige a trastorno por consumo de alcohol (AUD) y pérdida de peso, con aplicaciones potenciales en el tratamiento del binge drinking.
클리어마인드 의학 주식회사 (Nasdaq: CMND)가 미국 특허청으로부터 MEAI 기반의 폭음 행동 조절 프로그램에 대한 새로운 특허 승인을 받았습니다. 이 특허는 알코올 음료 소비 조절 및 아민 아미노인단의 투여를 통한 폭음 행동 제어 방법을 포함하며, 여기에는 회사의 혁신적인 환각 분자인 5-메톡시-2-아미노인단(MEAI)이 포함됩니다.
이 승인은 클리어마인드의 지적 재산 포트폴리오를 강화하며, 현재 미국, 유럽, 중국 및 인도와 같은 주요 관할권에서 19개 특허 가족에 걸쳐 29개의 허가된 특허를 포함하고 있습니다. MEAI는 알코올 소비 욕구를 줄이는 새로운 정신활성 분자로, 알코올과 유사한 가벼운 행복감을 제공하는 경험을 제공합니다. 클리어마인드의 MEAI 기반 주요 치료법은 알코올 사용 장애(AUD) 및 체중 감소를 목표로 하며, 폭주 음주 치료에 대한 잠재적 용도가 있습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a reçu une nouvelle approbation de brevet de l'Office américain des brevets et des marques pour son programme régulateur de comportement de binge basé sur MEAI. Le brevet couvre des méthodes de régulation de la consommation de boissons alcoolisées et de contrôle du comportement de binge par l'administration d'amine aminoindane, y compris 5-méthoxy-2-aminoindan (MEAI), la molécule psychédélique innovante de l'entreprise.
Cette approbation renforce le portefeuille de propriété intellectuelle de Clearmind, qui comprend maintenant 29 brevets accordés dans 19 familles de brevets dans des juridictions clés telles que les États-Unis, l'Europe, la Chine et l'Inde. MEAI est une molécule psychoactive novatrice qui réduit le désir de consommer de l'alcool tout en offrant une légère expérience euphorique semblable à celle de l'alcool. Le traitement phare de Clearmind basé sur MEAI cible le trouble de consommation d'alcool (AUD) et la perte de poids, avec des applications potentielles dans le traitement de la consommation excessive d'alcool.
Clearmind Medicine Inc. (Nasdaq: CMND) hat eine neue Patenterteilung vom United States Patent and Trademark Office für sein MEAI-basiertes Programm zur Regulierung von Binge-Verhalten erhalten. Das Patent umfasst Methoden zur Regulierung des Konsums von alkoholischen Getränken und zur Kontrolle von Binge-Verhalten durch die Verabreichung von Amine-Aminoindan, einschließlich 5-Methoxy-2-Aminoindan (MEAI), dem innovativen psychedelischen Molekül des Unternehmens.
Diese Genehmigung stärkt Clearminds geistiges Eigentum, das nun 29 erteilte Patente in 19 Patentfamilien in wichtigen Rechtssystemen wie den USA, Europa, China und Indien umfasst. MEAI ist ein neuartiges psychoaktives Molekül, das den Wunsch, Alkohol zu konsumieren, verringert und gleichzeitig ein mildes euphorisches Erlebnis ähnlich dem von Alkohol bietet. Die MEAI-basierte Hauptbehandlung von Clearmind zielt auf Alkoholgebrauchsstörung (AUD) und Gewichtsreduktion ab und hat potenzielle Anwendungen in der Behandlung von Binge-Drinking.
- Received U.S. patent approval for MEAI-based binge behavior regulator program
- Expanded intellectual property portfolio to 29 granted patents across 19 patent families
- Patent protection secured in key markets: U.S., Europe, China, and India
- MEAI shows potential in treating Alcohol Use Disorder (AUD) and binge drinking
- None.
Insights
This patent approval significantly strengthens Clearmind's position in the psychedelic therapeutics market. The expanded IP portfolio, now comprising 29 granted patents across 19 patent families, provides robust protection for MEAI-based treatments. This coverage in key markets like the U.S., Europe, China and India is important for future commercialization efforts.
The patent's focus on regulating alcohol consumption and controlling binge behavior addresses a substantial market need. With
The approval of this patent is a promising development in addiction treatment. MEAI's dual action of reducing alcohol cravings while providing a mild euphoric experience could be a game-changer for Alcohol Use Disorder (AUD) patients. This approach may address the psychological aspects of addiction more effectively than current treatments.
However, it's important to note that while this patent is significant, clinical trials are still needed to prove MEAI's efficacy and safety. The potential for treating both AUD and binge drinking is exciting, but we must remain cautious until we have robust clinical data. If successful, this could offer a new paradigm in addiction treatment, potentially reducing the
Clearmind's patent approval positions them well in the rapidly growing psychedelic therapeutics market, projected to reach
However, investors should consider the competitive landscape. Several companies are developing psychedelic-based treatments for various mental health conditions. Clearmind's success will depend on clinical trial outcomes, regulatory approvals and effective commercialization strategies. The company's extensive patent portfolio provides a competitive edge, but the path from patent to profitable product in the biotech sector is often long and uncertain.
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.
The approved patent claims cover, among other things, a method of regulating the consumption of alcoholic beverages and a method of controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest patent further bolsters Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “We are proud to continue leading the way in IP protection within this space. Expanding and maintaining our patent portfolio, particularly in the U.S., remains a key objective for us. We believe that we hold one of the largest portfolios in the market, covering our core areas: MEAI, binge behavior, addictions, mental disorders, as well as new psychedelic compounds and combinations identified and researched by our team.”
MEAI is a novel psychoactive molecule that reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience. It holds the potential to transform the lives of millions who struggle with moderating their alcohol intake. Clearmind’s MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss. AUD is a widespread condition that ranges from mild to severe and is characterized by an individual’s inability to control their alcohol consumption despite adverse social, occupational, or health consequences. Clearmind’s MEAI may also be effective in treating binge drinking, a potentially life-threatening addiction.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the advancement in its proprietary MEAI- based binge behavior regulator program and its goal to expand and maintain its patent portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What new patent has Clearmind Medicine (CMND) received approval for?
How many patents does Clearmind Medicine (CMND) now hold?
What is MEAI and what potential applications does it have for Clearmind Medicine (CMND)?
What is the main target of Clearmind Medicine's (CMND) MEAI-based flagship treatment?
